FATE Quote, Trading Chart, Fate Therapeutics Inc.
home / stock / fate / fate quote
$81.90 Last:
2.08% Change Percent:
$80.01 Open:
$81.90 Previous Close:
$82.165 High:
$78.4755 Low:
977,205 Volume:
06/21/2021 04:42:52 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
FATE Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-21 | 80.01 | 81.9 | 82.165 | 78.4755 | 977,205 |
| 2021-06-18 | 83.46 | 80.23 | 84.81 | 79.21 | 1,516,013 |
| 2021-06-17 | 82.28 | 84.21 | 86.165 | 81.73 | 1,463,709 |
| 2021-06-16 | 86.46 | 82.65 | 87.76 | 79.01 | 1,147,087 |
| 2021-06-15 | 89.99 | 86.79 | 90.62 | 85.26 | 1,081,544 |
| 2021-06-14 | 89.89 | 89.97 | 90.99 | 88.07 | 915,704 |
| 2021-06-11 | 88.05 | 89.75 | 90.99 | 86.4652 | 1,070,423 |
| 2021-06-10 | 82.52 | 88.42 | 88.95 | 80 | 1,827,637 |
| 2021-06-09 | 79.95 | 82.87 | 84.65 | 79.89 | 1,330,804 |
| 2021-06-08 | 77.78 | 78.48 | 79.68 | 76.49 | 818,614 |
| 2021-06-07 | 75.68 | 77 | 78.0199 | 73.16 | 1,368,139 |
| 2021-06-04 | 68.28 | 72.79 | 74.98 | 68.05 | 1,511,388 |
| 2021-06-03 | 68.13 | 67.25 | 69.01 | 65.13 | 924,357 |
| 2021-06-02 | 72.09 | 68.94 | 72.79 | 66.76 | 1,518,248 |
| 2021-06-01 | 76.86 | 72.46 | 77 | 71.85 | 897,328 |
| 2021-05-31 | 76.42 | 76.6 | 79.25 | 76.11 | 682,332 |
| 2021-05-28 | 76.42 | 76.6 | 79.25 | 76.11 | 578,349 |
| 2021-05-27 | 77.24 | 76.25 | 77.24 | 74.5 | 639,601 |
| 2021-05-26 | 75.33 | 76.47 | 76.87 | 73.05 | 617,661 |
| 2021-05-25 | 74 | 74.74 | 76.7 | 74 | 492,769 |
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical...
-
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...
-
8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell Therapy Favorable FT516 Safety Profile Was Observed; No FT516-related Seri...